Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The audit was completed with zero critical and zero major observations
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Subscribe To Our Newsletter & Stay Updated